Piramal Pharma Limited Reports Q3 FY25 Revenue of ₹22.04 Billion

Piramal Pharma Limited has announced its financial results for the third quarter of the fiscal year 2025, reporting consolidated revenue from operations of ₹22.04 billion. The company continues to focus on its core pharmaceutical segments, including Pharma Solutions, Critical Care, and Consumer Healthcare. Stakeholders are encouraged to review the detailed financial statements for comprehensive insights into the company's performance.

Source: Piramal Pharma Limited